Tygacil (tigecycline): Safety Communication on Increased Risk of Death
Infectious disease, critical care and pharmacy personnel are informed by the FDA about the new boxed warning added on the Tygacil prescribing information to warn about the increased risk of death.
Background of Tygacil (tigecycline)
Tygacil (tigecycline) is used for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP).
FDA Alert on Tygacil (tigecycline)
Additional analysis conducted by the FDA revealed a higher risk of death among patients receiving Tygacil versus other antibacterial drugs: 2.5% (66/2640) vs. 1.8% (48/2628), respectively at 95% confidence interval. The deaths resulted from worsening infections, complications of infection, or other underlying medical conditions.
FDA Recommendation on Tygacil (tigecycline)
“Health care professionals should reserve Tygacil for use in situations when alternative treatments are not suitable.”
AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.
If you or a loved one are in need of legal assistance concerning Law News you should get a lawyer on your side immediately. You will pay no attorney fees unless you win your case.
Email up to 10 Law News law firms in one click; by filling out the simple Free Case Evaluation form.
For additional info on Law News use the practice area links on the far right.